Kilitch Drugs (India) share news, announcements and annual reports
NSE: KILITCHBSE: 524500Pharmaceuticals & BiotechnologySmall Cap
Kilitch Drugs (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Sep 2010 on NSE
Last close ₹201.32down ₹7.82 (3.74%)BSE ₹201.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.14.
30 Oct: open ₹211.45, high ₹212.24, low ₹200.25
52-week range of traded prices to 30 Oct 2026
₹117.25Low, 30 Mar 2026₹267.90High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹704 Cr1,776th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 23.42
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.52
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,67341.3% delivered
Kilitch Drugs (India) shareholder meetings
56 filed, newest first. Page 2 of 2.
Oct 2012
Aug 2012
30 Aug · Meeting
Annual General Meeting of the Members of the Company will be held on September 29, 2012.
Nov 2011
Sep 2011
Aug 2011
3 Aug · Meeting
Kilitch Drugs (India) Limited had informed the Exchange that the Annual General Meeting of the Company will be held on August 30, 2011. The Company has now informed the Exchange that "The working Directors of the Company, who are well versed and have firsthand information and knowledge about the business operations of the Company unfortunately will not be in a position to attend the said AGM due to sudden business exigencies, which cannot be avoided. Further, the presence of such working Directors in the said AGM is all more important in order to answer any queries and in particular, about the operations of the Company, that may be raised by shareholders of the Company. Also, any queries raised by the members about future business plans can be well attended to only by such Directors who oversee day to day business operations of the Company. In view of the above, it is proposed to extend the date of Annual General Meeting from August 30, 2011 to September 10, 2011". Further the Company has informed that the dates of book closures as intimated remains unchanged from August 23, 2011 to August 30, 2011 [both days inclusive].
Jul 2011
27 Jul · Meeting
Book Closure for forthcoming Annual General Meeting and for the purpose of dividend is from August 23, 2011 to August 30, 2011 (both days inclusive). Further the Annual General Meeting of the Company will be held on August 30, 2011.